• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Feb. 20

Aurobindo Pharma Ltd (APL), the Hyderabad-based pharma major, has obtained regulatory approval for its Lisinopril tablets in different dosages of 5, 10 and 20 mg strengths from South Africa. Lisinopril is the generic version of Zestril marketed by Astra Zeneca. Lisinopril dihydrate is an effective, long lasting orally administered ACE inhibitor. It is used in the management of hypertension. Lisinopril belongs to a class of drugs that today commands a market size of $27 million in South Africa. According to a press release from APL, it is its seventh product to get the marketing authorisation approval from Medicines Control Council (MCC) of South Africa. The South African market is highly regulated. It is also very important in its geographical sphere. By getting the approval, APL can now participate in one of the key segments of the South African market, the release said.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
HLL to become Hindustan Unilever

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line